Evidence map›Paper›PMID 33594607›Full record

ReviewIn vitro cellular & developmental biology. Animal2021

Human reconstructed kidney models.

Seiji Kishi, Takuya Matsumoto, Takaharu Ichimura, Craig R Brooks

Abstract readReview
PubMed Publisher
In one paragraph

Review in In vitro cellular & developmental biology. Animal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Seiji KishiDepartment of General Medicine, Kawasaki Medical School, Kurashiki, 7010192, Japan. skishi-tks@umin.ac.jp.ORCID http://orcid.org/0000-0001-6205-1661
Takuya MatsumotoResearch Institute for Bioscience Products & Fine Chemicals, Ajinomoto Co., Inc, Kawasaki-ku, Kanagawa, 210-8681, Japan.
Takaharu IchimuraRenal Division, Brigham and Women's Hospital, Boston, MA, 02115, USA.
Craig R BrooksDepartment of Medicine, Division of Nephrology, Vanderbilt University Medical Center and Vanderbilt University School of Medicine, Nashville, TN, USA.
Ajinomoto (Japan) · JPBrigham and Women's Hospital · USKawasaki Medical School · JPVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human kidney, which consists of up to 2 million nephrons, is critical for blood filtration, electrolyte balance, pH regulation, and fluid balance in the body. Animal experiments, particularly mice and rats, combined with advances in genetically modified technology have been the primary mechanism to study kidney injury in recent years. Mouse or rat kidneys, however, differ substantially from human kidneys at the anatomical, histological, and molecular levels. These differences combined with increased regulatory hurdles and shifting attitudes towards animal testing by non-specialists have led scientists to develop new and more relevant models of kidney injury. Although in vitro tissue culture studies are a valuable tool to study kidney injury and have yielded a great deal of insight, they are not a perfect model. Perhaps, the biggest limitation of tissue culture is that it cannot replicate the complex architecture, consisting of multiple cell types, of the kidney, and the interplay between these cells. Recent studies have found that pluripotent stem cells (PSCs), which are capable of differentiation into any cell type, can be used to generate kidney organoids. Organoids recapitulate the multicellular relationships and microenvironments of complex organs like kidney. Kidney organoids have been used to successfully model nephrotoxin-induced tubular and glomerular disease as well as complex diseases such as chronic kidney disease (CKD), which involves multiple cell types. In combination with genetic engineering techniques, such as CRISPR-Cas9, genetic diseases of the kidney can be reproduced in organoids. Thus, organoid models have the potential to predict drug toxicity and enhance drug discovery for human disease more accurately than animal models.

Indexed as

Models, BiologicalAnimalsHumansInduced Pluripotent Stem CellsKidneyModels, AnimalOrganoidsTissue Engineering3D culture systemIn vitroIn vivoKidneyOrganoidOrgan-on-a-chipPluripotent stem cellsSingle-cell RNA sequencing

Identifiers

PMID33594607
OpenAlexW3130178696

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.